Empirical and theoretical approaches for the prediction of human hepatic clearance using chimeric mice with humanised liver: the use of physiologically based scaling, a novel solution for potential overprediction due to coexisting mouse metabolism

References

• Abernethy DR, Kaminsky LS, Dickinson TH. 1991. Selective inhibition of warfarin metabolism by diltiazem in humans. J Pharmacol Exp Ther. 257(1):411–415.
   PubMed Web of Science ®Google Scholar
• Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, Ellis E, Strom S, Kay MA, Finegold M, Grompe M, et al. 2007. Robust expansion of human hepatocytes in Fah–/–/Rag2–/–/Il2rg–/– mice. Nat Biotechnol. 25(8):903–910.
   PubMed Web of Science ®Google Scholar
• Barzi M, Pankowicz FP, Zorman B, Liu X, Legras X, Yang D, Borowiak M, Bissig-Choisat B, Sumazin P, Li F, et al. 2017. A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism. Nat Commun. 8(1):39.
   PubMedGoogle Scholar
• Berezhkovskiy LM, Khojasteh SC, Halladay JS, Hop CE. 2009. On the prediction of hepatic clearance using the diluted plasma in metabolic stability assay. J Pharm Sci. 98(6):1922–1927.
   PubMed Web of Science ®Google Scholar
• Chiba M, Ishii Y, Sugiyama Y. 2009. Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J. 11(2):262–276.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res. 10(7):1093–1095.
   PubMed Web of Science ®Google Scholar
• Di L, Feng B, Goosen TC, Lai Y, Steyn SJ, Varma MV, Obach RS. 2013. A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. Drug Metab Dispos. 41(12):1975–1993.
   PubMed Web of Science ®Google Scholar
• Di L, Obach RS. 2015. Addressing the challenges of low clearance in drug research. AAPS J. 17(2):352–357.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Kawai K, Mitsui T, Taniguchi K, Monnai M, Wakui M, Ito M, Suematsu M, Peltz G, Nakamura M, et al. 2011. The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem Biophys Res Commun. 405(3):405–410.
   PubMed Web of Science ®Google Scholar
• Ito K, Houston JB. 2004. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res. 21(5):785–792.
   PubMed Web of Science ®Google Scholar
• Ito S, Kamimura H, Yamamoto Y, Chijiwa H, Okuzono T, Suemizu H, Yamazaki H. 2020. Human plasma concentration-time profiles of troglitazone and troglitazone sulfate simulated by in vivo experiments with chimeric mice with humanized livers and semi-physiological pharmacokinetic modeling. Drug Metab Pharmacokinet. 35(6):505–514.
   PubMed Web of Science ®Google Scholar
• Jones RD, Jones HM, Rowland M, Gibson CR, Yates JWT, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, et al. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci. 100(10):4074–4089.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Ito S. 2016. Assessment of chimeric mice with humanized livers in new drug development: generation of pharmacokinetics, metabolism and toxicity data for selecting the final candidate compound. Xenobiotica. 46(6):557–569.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Ito S, Chijiwa H, Okuzono T, Ishiguro T, Yamamoto Y, Nishinoaki S, Ninomiya S-I, Mitsui M, Kalgutkar AS, et al. 2017. Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling. Xenobiotica. 47(5):382–393.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Ito S, Nozawa K, Nakamura S, Chijiwa H, Nagatsuka S-i, Kuronuma M, Ohnishi Y, Suemizu H, Ninomiya S-i, et al. 2015. Formation of the accumulative human metabolite and human-specific glutathione conjugate of diclofenac in TK-NOG chimeric mice with humanized livers. Drug Metab Dispos. 43(3):309–316.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Nakada N, Suzuki K, Mera A, Souda K, Murakami Y, Tanaka K, Iwatsubo T, Kawamura A, Usui T, et al. 2010. Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab Pharmacokinet. 25(3):223–235.
   PubMed Web of Science ®Google Scholar
• Kato K, Ohbuchi M, Hamamura S, Ohshita H, Kazuki Y, Oshimura M, Sato K, Nakada N, Kawamura A, Usui T, et al. 2015. Development of murine Cyp3a knockout chimeric mice with humanized liver. Drug Metab Dispos. 43(8):1208–1217.
   PubMed Web of Science ®Google Scholar
• Kitamura S, Sugihara K. 2014. Current status of prediction of drug disposition and toxicity in humans using chimeric mice with humanized liver. Xenobiotica. 44(2):123–134.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Uehara S, Kamimura H, Ikeda H, Maeda S, Hattori M, Nishiwaki M, Kato K, Yamazaki H. 2021. Human total clearance values and volumes of distribution of typical human cytochrome P450 2C9/19 substrates predicted by single-species allometric scaling using pharmacokinetic data sets from common marmosets genotyped for P450 2C19. Xenobiotica. 51(4):479–493.
   PubMed Web of Science ®Google Scholar
• Mehvar R. 2018. Clearance concepts: fundamentals and application to pharmacokinetic behavior of drugs. J Pharm Pharm Sci. 21(1s):88s–102s.
   PubMedGoogle Scholar
• Miyamoto M, Iwasaki S, Chisaki I, Nakagawa S, Amano N, Hirabayashi H. 2017. Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver. Xenobiotica. 47(12):1052–1063.
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Iwasaki S, Chisaki I, Nakagawa S, Amano N, Kosugi Y, Hirabayashi H. 2019. Prediction of human pharmacokinetics of long half-life compounds using chimeric mice with humanised liver. Xenobiotica. 49(12):1379–1387.
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Kosugi Y, Iwasaki S, Chisaki I, Nakagawa S, Amano N, Hirabayashi H. 2021. Characterization of plasma protein binding in two mouse models of humanized liver, PXB mouse and humanized TK-NOG mouse. Xenobiotica. 51(1):51–60.
   PubMed Web of Science ®Google Scholar
• Muruganandan S, Sinal CJ. 2008. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism. Clin Pharmacol Ther. 83(6):818–828.
   PubMed Web of Science ®Google Scholar
• Nakada N, Kawamura A, Kamimura H, Sato K, Kazuki Y, Kakuni M, Ohbuchi M, Kato K, Tateno C, Oshimura M, et al. 2016. Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans. Biopharm Drug Dispos. 37(1):3–14.
   PubMed Web of Science ®Google Scholar
• Nakayama K, Ito S, Suzuki M, Takubo H, Yamazaki H, Nomura Y. 2019. Prediction of human pharmacokinetics of typical compounds by a physiologically based method using chimeric mice with humanized liver. Xenobiotica. 49(4):404–414.
   PubMed Web of Science ®Google Scholar
• Nakayama K, Kamimura H, Suemizu H, Yoneda N, Nishiwaki M, Iwamoto K, Mizunaga M, Negoro T, Ito S, Yamazaki H, et al. 2020. Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data. Drug Metab Pharmacokinet. 35(4):389–396.
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Sanoh S, Ohta S. 2018. Chimeric mice with humanized liver: application in drug metabolism and pharmacokinetics studies for drug discovery. Drug Metab Pharmacokinet. 33(1):31–39.
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Sanoh S, Ohta S. 2019. Utility of chimeric mice with humanized liver for predicting human pharmacokinetics in drug discovery: comparison with in vitro-in vivo extrapolation and allometric scaling. Biol Pharm Bull. 42(3):327–336.
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. 283(1):46–58.
   PubMed Web of Science ®Google Scholar
• Ohtsuki S, Kawakami H, Inoue T, Nakamura K, Tateno C, Katsukura Y, Obuchi W, Uchida Y, Kamiie J, Horie T, et al. 2014. Validation of uPA/SCID mouse with humanized liver as a human liver model: protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases by LC-MS/MS. Drug Metab Dispos. 42(6):1039–1043.
   PubMed Web of Science ®Google Scholar
• Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JWT, Ku MS, Gibson CR, He H, et al. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessment of prediction methods of human clearance. J Pharm Sci. 100(10):4090–4110.
   PubMed Web of Science ®Google Scholar
• Roberts MS, Rowland M. 1986. Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. J Pharm Pharmacol. 38(3):177–181.
   PubMed Web of Science ®Google Scholar
• Sanoh S, Horiguchi A, Sugihara K, Kotake Y, Tayama Y, Ohshita H, Tateno C, Horie T, Kitamura S, Ohta S, et al. 2012. Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver. Drug Metab Dispos. 40(2):322–328.
   PubMed Web of Science ®Google Scholar
• Sanoh S, Naritomi Y, Fujimoto M, Sato K, Kawamura A, Horiguchi A, Sugihara K, Kotake Y, Ohshita H, Tateno C, et al. 2015. Predictability of plasma concentration-time curves in humans using single-species allometric scaling of chimeric mice with humanized liver. Xenobiotica. 45(7):605–614.
   PubMed Web of Science ®Google Scholar
• Sanoh S, Ohta S. 2014. Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics. Biopharm Drug Dispos. 35(2):71–86.
   PubMed Web of Science ®Google Scholar
• Sawada T, Yamaura Y, Higuchi S, Imawaka H, Yamazaki H. 2020. Predicting successful/unsuccessful extrapolation for in vivo total clearance of model compounds with a variety of hepatic intrinsic metabolism and protein bindings in humans from pharmacokinetic data using chimeric mice with humanised liver. Xenobiotica. 50(5):526–535.
   PubMed Web of Science ®Google Scholar
• Scheer N, Wilson ID. 2016. A comparison between genetically humanized and chimeric liver humanized mouse models for studies in drug metabolism and toxicity. Drug Discov Today. 21(2):250–263.
   PubMed Web of Science ®Google Scholar
• Sodhi JK, Wang HJ, Benet LZ. 2020. Are there any experimental perfusion data that preferentially support the dispersion and parallel-tube models over the well-stirred model of organ elimination? Drug Metab Dispos. 48:537–543.
   PubMed Web of Science ®Google Scholar
• Tateno C, Miya F, Wake K, Kataoka M, Ishida Y, Yamasaki C, Yanagi A, Kakuni M, Wisse E, Verheyen F, et al. 2013. Morphological and microarray analyses of human hepatocytes from xenogeneic host livers. Lab Invest. 93(1):54–71.
   PubMed Web of Science ®Google Scholar
• Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, et al. 2004. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol. 165(3):901–912.
   PubMed Web of Science ®Google Scholar
• Varma MVS, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD. 2010. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem. 53(3):1098–1108.
   PubMed Web of Science ®Google Scholar